Cargando…
New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment
SIMPLE SUMMARY: Our study investigated DNA methylation differences in easily accessible white blood cells (WBCs) between malignant pleural mesothelioma (MPM) cases and asbestos-exposed cancer-free controls. A multiple regression model highlighted that the methylation level of two single CpGs (cg0354...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199167/ https://www.ncbi.nlm.nih.gov/pubmed/34071989 http://dx.doi.org/10.3390/cancers13112636 |
_version_ | 1783707312762912768 |
---|---|
author | Cugliari, Giovanni Allione, Alessandra Russo, Alessia Catalano, Chiara Casalone, Elisabetta Guarrera, Simonetta Grosso, Federica Ferrante, Daniela Sculco, Marika La Vecchia, Marta Pirazzini, Chiara Libener, Roberta Mirabelli, Dario Magnani, Corrado Dianzani, Irma Matullo, Giuseppe |
author_facet | Cugliari, Giovanni Allione, Alessandra Russo, Alessia Catalano, Chiara Casalone, Elisabetta Guarrera, Simonetta Grosso, Federica Ferrante, Daniela Sculco, Marika La Vecchia, Marta Pirazzini, Chiara Libener, Roberta Mirabelli, Dario Magnani, Corrado Dianzani, Irma Matullo, Giuseppe |
author_sort | Cugliari, Giovanni |
collection | PubMed |
description | SIMPLE SUMMARY: Our study investigated DNA methylation differences in easily accessible white blood cells (WBCs) between malignant pleural mesothelioma (MPM) cases and asbestos-exposed cancer-free controls. A multiple regression model highlighted that the methylation level of two single CpGs (cg03546163 in FKBP5 and cg06633438 in MLLT1) are independent MPM markers. The epigenetic changes at the FKBP5 and MLLT1 genes were robustly associated with MPM in asbestos-exposed subjects. Interaction analyses showed that MPM cases and cancer-free controls showed DNAm differences which may be linked to asbestos exposure. ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm. Patients are usually diagnosed when current treatments have limited benefits, highlighting the need for noninvasive tests aimed at an MPM risk assessment tool that might improve life expectancy. Three hundred asbestos-exposed subjects (163 MPM cases and 137 cancer-free controls), from the same geographical region in Italy, were recruited. The evaluation of asbestos exposure was conducted considering the frequency, the duration and the intensity of occupational, environmental and domestic exposure. A genome-wide methylation array was performed to identify novel blood DNA methylation (DNAm) markers of MPM. Multiple regression analyses adjusting for potential confounding factors and interaction between asbestos exposure and DNAm on the MPM odds ratio were applied. Epigenome-wide analysis (EWAS) revealed 12 single-CpGs associated with the disease. Two of these showed high statistical power (99%) and effect size (>0.05) after false discovery rate (FDR) multiple comparison corrections: (i) cg03546163 in FKBP5, significantly hypomethylated in cases (Mean Difference in beta values (MD) = −0.09, 95% CI = −0.12|−0.06, p = 1.2 × 10(−7)), and (ii) cg06633438 in MLLT1, statistically hypermethylated in cases (MD = 0.07, 95% CI = 0.04|0.10, p = 1.0 × 10(−6)). Based on the interaction analysis, asbestos exposure and epigenetic profile together may improve MPM risk assessment. Above-median asbestos exposure and hypomethylation of cg03546163 in FKBP5 (OR = 20.84, 95% CI = 8.71|53.96, p = 5.5 × 10(−11)) and hypermethylation of cg06633438 in MLLT1 (OR = 11.71, 95% CI = 4.97|29.64, p = 5.9 × 10(−8)) genes compared to below-median asbestos exposure and hyper/hypomethylation of single-CpG DNAm, respectively. Receiver Operation Characteristics (ROC) for Case-Control Discrimination showed a significant increase in MPM discrimination when DNAm information was added in the model (baseline model, BM: asbestos exposure, age, gender and white blood cells); area under the curve, AUC = 0.75; BM + cg03546163 at FKBP5. AUC = 0.89, 2.1 × 10(−7); BM + cg06633438 at MLLT1. AUC = 0.89, 6.3 × 10(−8). Validation and replication procedures, considering independent sample size and a different DNAm analysis technique, confirmed the observed associations. Our results suggest the potential application of DNAm profiles in blood to develop noninvasive tests for MPM risk assessment in asbestos-exposed subjects. |
format | Online Article Text |
id | pubmed-8199167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81991672021-06-14 New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment Cugliari, Giovanni Allione, Alessandra Russo, Alessia Catalano, Chiara Casalone, Elisabetta Guarrera, Simonetta Grosso, Federica Ferrante, Daniela Sculco, Marika La Vecchia, Marta Pirazzini, Chiara Libener, Roberta Mirabelli, Dario Magnani, Corrado Dianzani, Irma Matullo, Giuseppe Cancers (Basel) Article SIMPLE SUMMARY: Our study investigated DNA methylation differences in easily accessible white blood cells (WBCs) between malignant pleural mesothelioma (MPM) cases and asbestos-exposed cancer-free controls. A multiple regression model highlighted that the methylation level of two single CpGs (cg03546163 in FKBP5 and cg06633438 in MLLT1) are independent MPM markers. The epigenetic changes at the FKBP5 and MLLT1 genes were robustly associated with MPM in asbestos-exposed subjects. Interaction analyses showed that MPM cases and cancer-free controls showed DNAm differences which may be linked to asbestos exposure. ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare and aggressive neoplasm. Patients are usually diagnosed when current treatments have limited benefits, highlighting the need for noninvasive tests aimed at an MPM risk assessment tool that might improve life expectancy. Three hundred asbestos-exposed subjects (163 MPM cases and 137 cancer-free controls), from the same geographical region in Italy, were recruited. The evaluation of asbestos exposure was conducted considering the frequency, the duration and the intensity of occupational, environmental and domestic exposure. A genome-wide methylation array was performed to identify novel blood DNA methylation (DNAm) markers of MPM. Multiple regression analyses adjusting for potential confounding factors and interaction between asbestos exposure and DNAm on the MPM odds ratio were applied. Epigenome-wide analysis (EWAS) revealed 12 single-CpGs associated with the disease. Two of these showed high statistical power (99%) and effect size (>0.05) after false discovery rate (FDR) multiple comparison corrections: (i) cg03546163 in FKBP5, significantly hypomethylated in cases (Mean Difference in beta values (MD) = −0.09, 95% CI = −0.12|−0.06, p = 1.2 × 10(−7)), and (ii) cg06633438 in MLLT1, statistically hypermethylated in cases (MD = 0.07, 95% CI = 0.04|0.10, p = 1.0 × 10(−6)). Based on the interaction analysis, asbestos exposure and epigenetic profile together may improve MPM risk assessment. Above-median asbestos exposure and hypomethylation of cg03546163 in FKBP5 (OR = 20.84, 95% CI = 8.71|53.96, p = 5.5 × 10(−11)) and hypermethylation of cg06633438 in MLLT1 (OR = 11.71, 95% CI = 4.97|29.64, p = 5.9 × 10(−8)) genes compared to below-median asbestos exposure and hyper/hypomethylation of single-CpG DNAm, respectively. Receiver Operation Characteristics (ROC) for Case-Control Discrimination showed a significant increase in MPM discrimination when DNAm information was added in the model (baseline model, BM: asbestos exposure, age, gender and white blood cells); area under the curve, AUC = 0.75; BM + cg03546163 at FKBP5. AUC = 0.89, 2.1 × 10(−7); BM + cg06633438 at MLLT1. AUC = 0.89, 6.3 × 10(−8). Validation and replication procedures, considering independent sample size and a different DNAm analysis technique, confirmed the observed associations. Our results suggest the potential application of DNAm profiles in blood to develop noninvasive tests for MPM risk assessment in asbestos-exposed subjects. MDPI 2021-05-27 /pmc/articles/PMC8199167/ /pubmed/34071989 http://dx.doi.org/10.3390/cancers13112636 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cugliari, Giovanni Allione, Alessandra Russo, Alessia Catalano, Chiara Casalone, Elisabetta Guarrera, Simonetta Grosso, Federica Ferrante, Daniela Sculco, Marika La Vecchia, Marta Pirazzini, Chiara Libener, Roberta Mirabelli, Dario Magnani, Corrado Dianzani, Irma Matullo, Giuseppe New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment |
title | New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment |
title_full | New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment |
title_fullStr | New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment |
title_full_unstemmed | New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment |
title_short | New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment |
title_sort | new dna methylation signals for malignant pleural mesothelioma risk assessment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199167/ https://www.ncbi.nlm.nih.gov/pubmed/34071989 http://dx.doi.org/10.3390/cancers13112636 |
work_keys_str_mv | AT cugliarigiovanni newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT allionealessandra newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT russoalessia newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT catalanochiara newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT casaloneelisabetta newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT guarrerasimonetta newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT grossofederica newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT ferrantedaniela newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT sculcomarika newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT lavecchiamarta newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT pirazzinichiara newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT libenerroberta newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT mirabellidario newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT magnanicorrado newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT dianzaniirma newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment AT matullogiuseppe newdnamethylationsignalsformalignantpleuralmesotheliomariskassessment |